Trial Profile
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Amdizalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Hutchison MediPharma; HUTCHMED
- 27 Feb 2024 Planned End Date changed from 31 Aug 2023 to 31 Dec 2024.
- 27 Feb 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Jul 2024.
- 11 Jan 2023 Status changed from recruiting to active, no longer recruiting.